23andMe Holding Co. (ME) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
23andMe Holding Co. (ME) trades at $0.6063 with AI Score 50/100 (Grade B). 23andMe Holding Co. is a consumer genetics and therapeutics company. They offer genetic testing services and are developing novel therapies. Market cap: $15.3M, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: May 10, 2026Analyst Coverage for ME: ME does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ME against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ME: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
23andMe Holding Co. (ME) Healthcare & Pipeline Overview
23andMe Holding Co. is a consumer genetics company providing personalized genetic reports and therapeutic development. Through its two segments, Consumer & Research Services and Therapeutics, the company leverages genetic insights for drug discovery and personalized healthcare, operating in the competitive medical diagnostics and research sector.
What Is the Investment Thesis for ME?
23andMe Holding Co. presents a unique investment opportunity within the healthcare sector, driven by its dual focus on consumer genetics and therapeutic development. The company's gross margin of 54.2% indicates strong pricing power in its consumer services. However, the company's negative profit margin of -134.7% raises concerns about profitability. Key growth catalysts include expanding its therapeutic pipeline and leveraging its genetic database for drug discovery. Potential risks include regulatory hurdles and competition in the genetic testing market. Investors should monitor the company's progress in achieving profitability and successfully commercializing its therapeutic assets.
Based on FMP financials and quantitative analysis
ME Key Highlights
- Gross Margin of 54.2% indicates strong pricing power in its consumer services segment.
- Market Cap of $15.3M reflects its current valuation in the market.
- Profit Margin of -134.7% highlights ongoing challenges with profitability.
- Collaboration with GlaxoSmithKline provides potential for leveraging genetic insights in drug development.
- Beta of 1.20 suggests higher volatility compared to the overall market.
Who Are ME's Competitors?
ME is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DHR Danaher Corporation | $201.11 | -1.33% | $142B | 71 |
| IDXX IDEXX Laboratories, Inc. | $563.81 | -0.64% | $44.5B | 93 |
| A Agilent Technologies, Inc. | $130.26 | -0.91% | $36.8B | 84 |
| ILMN Illumina, Inc. | $184.68 | -1.06% | $27.9B | 91 |
| GH Guardant Health, Inc. | $155.87 | +0.56% | $20.7B | 34 |
| LDDD Longduoduo Company Limited | $0.51 | +0.00% | $15.3M | 51 |
| MYNZ Mainz Biomed B.V. | $3.59 | +0.84% | $14.7M | 55 |
| QUCY QUCY | $1.16 | -5.69% | $14.5M | 55 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ME's Key Strengths?
- Proprietary genetic database
- Established brand recognition
- Strategic partnerships
- Innovative therapeutic pipeline
What Are ME's Weaknesses?
- Negative profit margin
- Limited product diversification
- Dependence on regulatory approvals
- High marketing expenses
What Could Drive ME Stock Higher?
- Clinical trial results for therapeutic candidates.
- Expansion of genetic testing services.
- Strategic partnerships with pharmaceutical companies.
- Data monetization initiatives.
What Are the Key Risks for ME?
- Financial-distress signal — its Altman Z-Score of -26.64 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles for genetic testing and therapeutic products.
- Competition in the genetic testing market.
- Data privacy and security concerns.
- Economic downturn impacting consumer spending.
What Are the Growth Opportunities for ME?
- Expanding Therapeutic Pipeline: 23andMe has the opportunity to leverage its extensive genetic database to identify and develop novel therapies across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases. This expansion can drive revenue growth and enhance the company's long-term value. The market for targeted therapies is projected to reach $150 billion by 2028, presenting a significant opportunity for 23andMe.
- Strategic Partnerships: Collaborating with pharmaceutical companies like GlaxoSmithKline can accelerate the development and commercialization of new drugs. These partnerships provide access to funding, expertise, and distribution channels, enabling 23andMe to expand its reach and impact. The global pharmaceutical market is expected to reach $1.5 trillion by 2026, offering substantial opportunities for strategic alliances.
- Personalized Healthcare Solutions: The company can further develop personalized healthcare solutions based on individual genetic profiles. This includes providing tailored recommendations for diet, exercise, and medication, improving patient outcomes and driving customer loyalty. The personalized medicine market is projected to reach $4.2 billion by 2028, driven by increasing demand for individualized treatment approaches.
- Geographic Expansion: 23andMe can expand its operations into new geographic markets, particularly in Asia and Europe, to reach a broader customer base. This expansion can drive revenue growth and diversify the company's revenue streams. The global genetic testing market is expected to reach $25 billion by 2027, with significant growth potential in emerging markets.
- Data Monetization: 23andMe has the opportunity to monetize its extensive genetic database by providing anonymized data to researchers and pharmaceutical companies for drug discovery and development purposes. This can generate a new revenue stream and contribute to the advancement of medical research. The market for healthcare data analytics is projected to reach $68 billion by 2028, driven by increasing demand for data-driven insights.
What Opportunities Does ME Have?
- Expanding therapeutic pipeline
- Strategic partnerships
- Personalized healthcare solutions
- Geographic expansion
What Threats Does ME Face?
- Regulatory hurdles
- Competition in the genetic testing market
- Data privacy concerns
- Economic downturn
What Are ME's Competitive Advantages?
- Proprietary genetic database.
- Established brand recognition in the consumer genetics market.
- Strategic partnerships with pharmaceutical companies.
- Intellectual property related to drug targets.
What Does ME Do?
Founded in 2006 and headquartered in South San Francisco, California, 23andMe Holding Co. has established itself as a prominent player in the consumer genetics and therapeutics industry. The company operates through two primary segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services segment offers a suite of genetic reports to customers, providing insights into their ancestral origins, potential genetic health risks, and carrier status for certain conditions. These reports are generated from saliva samples collected through its proprietary spit kit. The Therapeutics segment focuses on the discovery, development, and commercialization of novel therapies across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases. 23andMe collaborates with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights for drug development. The company's evolution has been marked by expanding its genetic testing services and advancing its therapeutic pipeline, positioning itself at the intersection of personalized healthcare and drug discovery.
What Products and Services Does ME Offer?
- Provides genetic reports on ancestry.
- Offers insights into potential genetic health risks.
- Determines carrier status for certain genetic conditions.
- Develops novel therapies for various diseases.
- Collaborates with pharmaceutical companies for drug discovery.
- Offers out-licensing of intellectual property related to drug targets.
How Does ME Make Money?
- Generates revenue from the sale of genetic testing kits.
- Derives income from providing genetic reports and analysis.
- Focuses on drug development and commercialization.
- Out-licenses intellectual property associated with drug targets.
- Partnerships with pharmaceutical companies for drug development.
What Industry Does ME Operate In?
23andMe Holding Co. operates within the rapidly evolving medical diagnostics and research industry. The market is characterized by increasing demand for personalized medicine and genetic testing services. Key competitors include Danaher Corporation (DHR), IDEXX Laboratories, Inc. (IDXX), Agilent Technologies, Inc. (A), Illumina, Inc. (ILMN), and Guardant Health, Inc. (GH). The company's success depends on its ability to innovate, navigate regulatory challenges, and effectively commercialize its products and services. The industry is also influenced by advancements in genomics and data analytics, driving the development of new diagnostic and therapeutic solutions.
Who Are ME's Key Customers?
- Individuals seeking information about their ancestry.
- People interested in understanding their genetic health risks.
- Researchers and pharmaceutical companies.
- Patients seeking personalized healthcare solutions.
Company Profile
23andMe Holding Co. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Joseph Selsavage. ME has traded publicly since 2020.
FY2027 estForward Outlook
Wall Street analysts project 23andMe Holding Co. revenue of about $251.4M for fiscal 2027, with EPS near $-7.80.
F-Score 3/9Financial Health
23andMe Holding Co.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -26.64 places it in the distress zone, a signal of elevated financial risk.
ME Valuation & Market Position
With a $15.3M market cap, 23andMe Holding Co. sits in the micro-cap segment of the market. Relative to its peer group, ME's quantitative score of 50/100 is below the peer average of 75/100.
Net buyingInsider Activity
The most recent 7 insider filings for 23andMe Holding Co. break down as 2 sales and 5 purchases. On net that is roughly 2.4M shares acquired (about $100K) — insiders putting money in tends to read as conviction.
ME Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying has signaled confidence in the company's future, suggesting that key stakeholders believe in its growth potential.
- Community sentiment has shifted positively as users report increased satisfaction with the platform, enhancing brand loyalty.
- Innovations in genetic testing and personalized health insights have garnered attention, positioning 23andMe as a leader in a growing market.
- Increased media coverage and partnerships with healthcare providers have raised awareness, potentially expanding its customer base.
Bear Case
- Concerns over regulatory scrutiny in the genetic testing space could hinder growth and lead to operational challenges.
- Negative sentiment has emerged from discussions about data privacy, impacting user trust and engagement with the platform.
- Market competition is intensifying as new players enter the genetic testing arena, which may dilute 23andMe's market share.
- Recent earnings reports have highlighted challenges in user growth, raising questions about the sustainability of its business model.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ME Latest News
-
Marco Rubio Says President Lula 'Put His Ego Ahead of Making a Deal' as Trump Slaps Brazil With 25% Tariffs
benzinga · Jul 16, 2026
-
Americold: The High-Yield Re-Rating Story Isn't Over
All Articles on Seeking Alpha · Jun 30, 2026
-
Europe’s rearmament drive is sustaining 195,000 US defence jobs, Nato chief says
International homepage · Jun 30, 2026
-
Texas Instruments: An AI Beneficiary, But Not Cheap Enough To Buy
All Articles on Seeking Alpha · Jun 30, 2026
ME Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ME.
Price Targets
Wall Street price target analysis for ME.
ME MoonshotScore
What does this score mean?
The MoonshotScore rates ME 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
Marco Rubio Says President Lula 'Put His Ego Ahead of Making a Deal' as Trump Slaps Brazil With 25% Tariffs
Americold: The High-Yield Re-Rating Story Isn't Over
Europe’s rearmament drive is sustaining 195,000 US defence jobs, Nato chief says
Texas Instruments: An AI Beneficiary, But Not Cheap Enough To Buy
Leadership: Joseph Selsavage
CEO
Information on Joseph Selsavage's background is not available in the provided context. Therefore, a detailed biography cannot be provided. Further research would be needed to gather information on his career history, education, and previous roles.
Track Record: Information on Joseph Selsavage's track record is not available in the provided context. Therefore, a detailed analysis of his key achievements, strategic decisions, and company milestones under his leadership cannot be provided. Further research would be needed to gather this information.
ME Healthcare Stock FAQ
What does the AI Score mean for ME?
ME holds an AI Score of 50/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. 23andMe Holding Co. is a consumer genetics and therapeutics company. They offer genetic testing services and are developing novel therapies.
What does 23andMe Holding Co. do?
23andMe Holding Co. operates as a consumer genetics and therapeutics company. It provides a suite of genetic reports to customers, offering insights into their ancestral origins, potential genetic health risks, and carrier status for certain conditions. Additionally, the company focuses on the discovery, development, and commercialization of novel therapies across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases.
What do analysts say about ME stock?
Analyst consensus on 23andMe Holding Co. (ME) is mixed, reflecting the company's unique position in the consumer genetics and therapeutics market. Key valuation metrics, such as market capitalization and revenue growth, are closely monitored. Growth considerations include the company's ability to expand its therapeutic pipeline, monetize its genetic database, and navigate regulatory challenges.
What are the main risks for ME?
The main risks for 23andMe Holding Co. include regulatory hurdles for genetic testing and therapeutic products, competition in the genetic testing market, data privacy and security concerns, and the potential impact of an economic downturn on consumer spending. The company's success depends on its ability to navigate these challenges effectively.
What are the key factors to evaluate for ME?
23andMe Holding Co. (ME) holds an AI score of 50/100 (moderate). Not financial advice.
How frequently does ME data refresh on this page?
ME's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ME's recent stock price performance?
23andMe Holding Co. (ME) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary genetic database. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ME overvalued or undervalued right now?
23andMe Holding Co. (ME) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ME before investing?
Before investing in 23andMe Holding Co. (ME), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Analyst consensus and valuation metrics are based on publicly available sources.
- Risk assessment is based on general industry knowledge and company-specific information.